According to Syqe Medical, Australia’s Therapeutic Goods Administration (TGA) has approved the company’s SyqeAir cannabis inhaler, which includes 60 metered doses of milled cannabis flowers. The cartridge-based inhaler will now appear in the Australian Register of Therapeutic Goods (ARTG). Novachem sponsored the application and will distribute SyqeAir in Australia.
The Syqe inhaler has been approved in Canada since 2021 and has been marketed in Israel since 2019. Syqe says that it recently reached an agreement with Israel’s Ministry of Defense to supply SyqeAir to military veterans.
SyqeAir CEO Hagit Kamin commented, “Receiving ARTG approval in Australia is a significant achievement for our company. We are excited to collaborate with healthcare professionals and organizations in Australia to expand access to the SyqeAir Inhaler, enabling patients to benefit from reliable and consistent medicinal cannabis treatment.”
Novachem Medical Products Manager Andrew Heath said, “This is a landmark achievement for both Novachem and Syqe Medical. The SyqeAir Inhaler represents a significant step forward in the medicinal cannabis industry, offering patients and healthcare professionals a safer, consistent, and easy-to-use delivery system. Additionally, this approval opens up new reimbursement opportunities, making this advanced treatment more accessible to patients who need it most.”
Read the Syqe Medical press release.
